Asp Isotopes Inc. · NASDAQ:ASPI
Asp Isotopes — Investor Presentation (January 2024)
39 slides from Asp Isotopes's investor presentation, January 2024
Slide 1: Corporate Overview
Corporate Overview January 2024 © ASP Isotopes Inc. 1
Slide 2: Forward Looking Statements
Forward Looking Statements Forward Looking Statements This presentation contains, and our officers and representatives may from time to time make, “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looki
Slide 3: ASP Isotopes: At a Glance
ASP Isotopes: At a Glance 1. Proven & Proprietary Technology ASPI's advanced technology leverages 20 years of R&D history to enrich isotopes in varying levels of atomic mass. Its innovative technology will enable the company to manufacture a diverse range of isotopes, which will ASP Isotopes (NASDAQ
Slide 4: Current Group Structure
Current Group Structure • Most customers contract through ASPI Guernsey ASP Isotopes Inc • Intellectual Property largely owned by ASPI (UK) Delaware (US) NASDAQ (ASPI) ASP Isotopes (Guy) Ltd ASP Isotopes (UK) Ltd Guernsey United Kingdom 51% ASP Isotopes (Pty) Ltd South Africa Quantum Leap PET Labs (
Slide 5: Target Milestones
Target Milestones MARKET MILESTONES OPERATIONAL MILESTONES 1. Secure at least 2 additional supply agreements 1. Start commercial production of isotopes at our for isotopes critical for new technologies and enrichment facilities in South Africa. – Early 2024 healthcare. 2. Start constructing a first
Slide 6: Isotope Production is Essential for National and Global Security
Isotope Production is Essential for National and Global Security Isotopes have one of the most severely compromised supply chains of Historical Isotope any material in the world and are Critical to the following end markets. Market Producers1 Nuclear Power Europe Generation 15% Space Quantum Explora
Slide 7: What Is An Isotope?
What Is An Isotope? Silicon (Si) has 3 stable isotopes, where 28Si content in the natural mix 28Si 92.2% is only 92.2%. Isotopes are like identical twins or triplets: very similar in most aspects, except for a few subtle differences. 29Si 4.7% • Isotopes are two or more atoms of the same chemical el
Slide 8: Summary of ASP Technologies
Summary of ASP Technologies Aerodynamic Separation Process (ASP) Quantum Enrichment Quantum enrichment technology employs precisely The Aerodynamic separation process utilizes gaseous tuned lasers and quantum mechanical principles to diffusion via a stationary wall centrifuge paired with efficiently
Slide 9: ASP Isotopes: Technology Highlights
ASP Isotopes: Technology Highlights 1. Cost-Effective Isotope enrichment facilities using our technology can be constructed at a fraction of capital cost and time vs. traditional isotope separation facilities. 2. Modular, Scalable Design The plants can be small in footprint and modular in design, al
Slide 10: Isotopes of Interest
Isotopes of Interest Under Anticipated Isotopes End-Market R&D Stage R&D Evaluation Construction Market Entry Carbon-14 Pharma & Agrochem 2024 Silicon-28 Quantum Computing 2024 Germanium-70/72/74 Quantum Computing 2025 Molybdenum-100 2024 Nuclear Medicine Molybdenum-98 2024 Zinc- 67/68 2025 Ytterbiu
Slide 11: The Changing Face of Nuclear Medicine
The Changing Face of Nuclear Medicine • A Rapidly Growing Market driven by Theranostics (PET Diagnostics + Alpha Therapeutic Therapeutics). Radiopharmaceuticals • New Product Approvals + Significant Increase in R&D • > $3.5 billion of Capital Formation Beta Therapeutic Key Products • Recent Product
Slide 12: Isotope End Markets: Nuclear Medicine
Isotope End Markets: Nuclear Medicine ISOTOPES OF INTEREST 14C 99Tc 68Ga 67Cu 64Cu 177Lu END MARKET Carbon-Dating PET Scan imaging Oncology Oncology SPECT Scan Treatment Treatment Pharmacokinetic Imaging Oncology (Non-Hodgkin (Neuroendocrine Tracing Treatment lymphoma, Prostate Tumors NETs) Cancer,
Slide 13: Isotope End Markets: Carbon-14
Isotope End Markets: Carbon-14 (14C) A scientific technique used to track the passage of a Radiolabeling molecule. The technique incorporates a radioisotope ASPI’s Carbon-14 enrichment facility through a reaction, cell, organism, biological system, or metabolic pathway. Used as a radiolabeling compo
Slide 14: Isotope End Markets: Molybdenum-100
Isotope End Markets: Molybdenum-100 (100Mo) Imaging Agent Distribution Single-photon emission 99Tc computed tomography (SPECT) It is estimated that 80-85% of all Technetium-99 SPECT procedures utilize Global Market Size6 Technetium-998 99Tc Global Market Size7 $4.61B $4.17B Current Isotope Conversio
Slide 15: Isotope End Markets: Zinc-68
Isotope End Markets: Zinc-68 (68Zn) Imaging Agent Distribution 68Ga Positron emission tomography Over 90% of prostate Cancers (PET) Gallium-68 Over-Express PSMA, and Ga68 hybrid therapy has a 76/97% Global Market Size4 68Ga Global Market Size5 Sensitivity/Specificity identification $1.15B $127M rate
Slide 16: Isotope End Markets: Ytterbium-176
Isotope End Markets: Ytterbium-176 (176Yb) 177Lutetium Based Drugs set to Become a Blockbuster Category Initially driven by Pluvicto (Novartis) Efficacy Results in VISION Kaplan-Meier Plot of Overall Survival in VISION Consensus Forecasts (US$) for Pluvicto Traditional route starting with 177Lu The
Slide 17: Silicon-28: Enabling Quantum Computing
Silicon-28: Enabling Quantum Computing Quantum Computers are expected to be 1000x more powerful than today’s conventional computers and are widely anticipated to create new opportunities in medicine, artificial intelligence, cybersecurity, finance, logistics, and other industries. The semiconductor
Slide 18: Future Growth Plans to Scale ASPI Business into new Isotopes
Future Growth Plans to Scale ASPI Business into new Isotopes Iceland identified as the likely optimal location for expansion: Iceland Electricity Network • Iceland’s policy is to attract high-tech green industry into the country to support its own long-held ESG-based ethos. • Likely government suppo
Slide 19: Quantum Leap Energy
ae IANTUM LEAP ENERGY ASP isotopes) ©
Slide 20: The Equation is a Well-Known Fact... Solving it is not Straightforward
The Equation is a Well-Known Fact... Solving it is not Straightforward Global Electricity Production needs to double by 2050. Protesting is not going to Solve … The Solution Requires the Equation… Innovation and Investment At the same time, the world needs to achieve carbon neutrality. © ASP Isotope
Slide 21: The Global Necessity for Increased Green Nuclear Energy
The Global Necessity for Increased Green Nuclear Energy Increasing Demand for Energy Security Increasing Focus on Energy Nuclear Power By Country ▪ To reach Net Zero emissions by ▪ Russia is responsible for 35% of ▪ During COP28, 24 countries backed a 2050, the world must increase enriched uranium g
Slide 22: Nuclear Power Uptake Benefits
Nuclear Power Uptake Benefits Low Carbon Energy Constant and Cost Competitive Essential Energy Controllable Energy Energy Diversity Nuclear power is one of the Nuclear power provides Nuclear power provides Renewable energies world's energy sources that continuous electricity continuous electricity (
Slide 23: SMR (Small Modular Reactors) = Next Wave in Nuclear Energy
SMR (Small Modular Reactors) = Next Wave in Nuclear Energy The world is moving to a new type of nuclear reactor: SMR TerraPower’s Natrium ▪ Modular, smaller size (50 MWe to 300 MWe) reactors allowing greater flexibility in deployment ▪ Designed for production-line manufacturing rather than conventio
Slide 24: HALEU Supply Issue Looming for SMR Reality
Annual US Demand Growth for HALEU HALEU Supply Issue 700 Looming for SMR Reality 600 500 ▪ Current commercial LWRs use low-enriched uranium 400 (LEU) which has less than 5% 235U content. 300 ▪ Many SMRs and advanced reactors will require High 200 Assay Low Enriched Uranium (HALEU) with 235U enrichme
Slide 25: Comparing and Contrasting Enrichment Methods
Comparing and Contrasting Enrichment Methods Atomic Vapor Laser Molecular Laser Isotope Quantum Enrichment Gaseous Diffusion Centrifugation Isotope Separation Silex Systems Separation (MLIS) (used by QLE) (AVLIS) Capital 1/10 of Cost High capital cost Low Capital, small size Low Capital, small size
Slide 26: What is Quantum Enrichment?
What is Quantum Enrichment? ▪ Quantum Enrichment was derived from AVLIS (Atomic Vapor Laser Isotope Separation). Isotopes of every element also have unique spectroscopic “signatures” defined by the electromagnetic radiation or “light” absorbed by their atoms from electron transitions. ▪ Quantum enri
Slide 27: Nuclear Fuel Cycle
Nuclear Fuel Cycle Mining and Conversion Fuel Power Enrichment Deconversion Milling Fabrication Generation Fuel U3O8 UF6 UF6 UO2 Assemblies Depleted Used UF6 PuO2 Fuel RepU Storage Storage Reprocessing Fission Products Disposal Nuclear Fuel Cycle Front End Back End © ASP Isotopes Inc. 27
Slide 28: Nuclear Fuel Chain Prices
Nuclear Fuel Chain Prices • Multiple Macroeconomic factors caused by geopolitics, pandemics, blocked canals, and weather, have caused long-term Uranium price indicators to continue to rise to 10-year highs. • Front-end nuclear fuel markets highlight numerous and increasing risks facing the productio
Slide 29: Implications for HALEU
Implications for HALEU • If available (currently there is no western supplier of HALEU), HALEU would likely cost >>$18,000 per Kg. • Many SMR company’s based their business plans assuming HALEU <<$10,000 per Kg HALEU Component Costs HALEU Component Costs 2010- 2023 Jan 2024 © ASP Isotopes Inc. 29
Slide 30: Current Implications of Depleted UF6 tails
Current Implications of Depleted UF6 tails Depleted tails from other Uranium enrichers produce nuclear waste. The management of this waste is becoming a problem. We believe that our Process has the ability to process this waste into HALEU Potentially providing a solution to this growing environmenta
Slide 31: Investment Thesis
Investment Thesis 1. Proven & Proprietary Technology ASPI's advanced technology platform leverages 20 years of R&D history to enrich isotopes in varying levels of atomic mass. Its innovative technology will enable the company to manufacture a diverse range of isotopes, which will meet the growing de
Slide 32: Appendix
Appendix Company Timeline Management Team © ASP Isotopes Inc. 32
Slide 33: Company History
Company History October 2021 July 2022 March 2023 June 2023 Nov 2023 • ASP Isotopes wins competitive Acquisition of the Small-Scale ASP announces the ASP Secures $9m Supply • ASP acquires 51% of the auction for Klydon Large-scale Plant enrichment facility from commissioning of its Contract with US o
Slide 34: ASPI: Employees Demographics
ASPI: Employees Demographics We now have over 70 employees. 19% of employees have PhDs 41% of employees have advanced degrees or higher Employees By Nationality Employees By Role Radioisotope Non South Engineering Production African 15% and 3% distribution 23% Plant Adminstration construction and So
Slide 35: ASP Isotopes: Leadership Team
ASP Isotopes: Leadership Team PAUL MANN HENDRIK STRYDOM, PhD GERDUS KEMP, MD, PhD Chairman, and CEO Director, Chief Technology Officer Medical Director, CEO PET Labs ▪ Co-founded ASP Isotopes in ▪ Co-developer of “Aerodynamic ▪ CEO Pet-Labs, a South African September 2021 Separation Process” (ASP) a
Slide 36: ASP Isotopes: Senior Management
ASP Isotopes: Senior Management Xandra Van Heerden, PhD Heino Van Wyk Ben Swanapol Robert Ainscow Head of R&D Head of Engineering Head of Chemistry Chief Financial Officer ▪ Head of Research & ▪ Process engineer with ▪ Head of Chemistry at ASP. ▪ Co-Founder, ASP Development at ASP. design experience
Slide 37: ASP Isotopes: Scientific Advisors
ASP Isotopes: Scientific Advisors PROF EINAR RONANDER, PhD Chief Scientific Advisor ▪ Globally recognized as a leading scientist in the field of isotope separation for medical and industrial applications ▪ Pioneered the Molecular Laser Isotope Separation (MLIS) and the Atomic Vapour Laser Isotope Se
Slide 38: ASP Isotopes: Non-Executive Directors
ASP Isotopes: Non-Executive Directors PROF MIKE GORLEY, PhD TODD WIDER, MD DUNCAN MOORE, PhD JOSHUA DONFELD Director Director Director Director ▪ Director of Fusion ▪ Executive Chairman and ▪ Partner at East West ▪ 20+ years Investing Technology at the U.K. Chief Medical Officer, Capital Partners, e
Slide 39: Data Sources
Data Sources 1. Wang, Yiwei et al. “Production Review of Accelerator-Based Medical Isotopes.” Molecules (Basel, Switzerland) vol. 27,16 5294. 19 Aug. 2022, doi:10.3390/molecules27165294. 2. B.L. Zhukov et al. "Production of medical radionuclides in Russia: Status and future - a review.” Applied Radi